Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Viral ligands for Natural Cytotoxicity Receptors (NCRs) NKp46 and NKp44 are a diverse group of pathogen-encoded proteins that facilitate viral recognition by the innate immune system [NIH, 2021; Frontiers in Immunology, 2019]. The most prominent members include the hemagglutinin (HA) of influenza viruses and the hemagglutinin-neuraminidase (HN) of paramyxoviruses, which bind to specific sialylated O-glycans on the extracellular domains of NKp46 and NKp44 [Blood, 2004; NIH, 2025]. This binding event triggers a signaling cascade in Natural Killer (NK) cells, leading to the release of cytotoxic granules and the lysis of infected cells [NIH, 2021; ACS, 2009]. Beyond influenza, other viral proteins such as the West Nile Virus E protein and poxvirus hemagglutinins also serve as ligands for these receptors [NIH, 2021; PLOS Pathogens, 2010]. Viruses have developed sophisticated evasion mechanisms to disrupt this interaction, such as using viral neuraminidase to remove the essential sialic acids from the NCRs [NIH, 2014; NIH, 2021]. Therapeutic strategies targeting this axis include neuraminidase inhibitors that preserve NK cell recognition and the development of monoclonal antibodies or fusion proteins designed to enhance or mimic these natural immune-activating interactions [NIH, 2021; Frontiers in Immunology, 2019].
Binding of viral ligands (such as hemagglutinin) to sialylated residues on the NKp46 and NKp44 receptors triggers NK cell-mediated cytotoxicity and cytokine production against infected cells [NIH, 2021; Blood, 2004].
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Viral ligands for Natural Cytotoxicity Receptors NKp46 and NKp44 (Viral NCR ligands).